Ashvattha Therapeutics is a clinical-stage biotech company focused on developing novel dendrimer-based therapies to treat unmet medical needs in inflammatory, oncology, and ocular diseases. The company is advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation.

Ashvattha Therapeutics

Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.

Tribe Capital

Helios Capital

Plum Alley Investments

Sand Hill Angels

Natural Capital

Bhaskar Ghosh

Kingsley Advani

Kyle Wang

Phil Deutch

Sakya Duvvuru

Sam Altman

EcoR1 Capital

Modi Ventures

Huadong Medicine

Natural Capital Investment Fund

Ashvattha Therapeutics, Inc.

In case you missed it, our co-founder @Kannan Rangaramanujam, Ph.D., discussed the benefits of nanomedicines delivered systemically and what it could mean for patients with eye diseases (AMD and DME). Read more here: https://brnw.ch/21wFXt3


We are pleased to share that Mehdi Paborji, PhD, has joined the Ashvattha team as Senior Vice President of Technical Operations.

Dr. Paborji's experience in #DrugDevelopment and #manufacturing will be valuable as we plan next steps for our clinical-stage programs following Phase 2 readouts expected in 1H 2024 and as we advance several of our #nanomedicines through IND-enabling studies. Read more about his experience and role here:
 https://brnw.ch/21wFNMo

Happy New Year from Ashvattha Therapeutics! We are excited for the year ahead and look forward to continuing our progress in developing a new class of #nanomedicines for patients with ophthalmic and neurological diseases.


As 2023 comes to an end, we reflect on our year of firsts in advancing precision #nanomedicine therapeutics closer to patients.

✅ First patient dosed in the Phase 2 chronic dosing study of our anti-angiogenic therapeutic candidate for #WetAMD and #DME.

✅ First patient enrolled in the Phase 1 study of our imaging agent in individuals with #ALS and healthy volunteers.

We look forward to sharing data from these #ClinicalTrials in 2024! Read more: https://brnw.ch/21wFF76


Our team is grateful for the support from our partners and community which enabled us to advance our #nanomedicine therapeutics further in the clinic this year. Happy holidays from the Ashvattha team!


COM:AVTTX

Ashvattha Therapeutics

Financials Not Available